Reactive Metabolites and AGE-RAGE-Mediated Inflammation in Patients following Liver Transplantation

Table 2

Plasma levels of total antioxidant capacity (TAC), soluble receptor for advanced glycation endproducts (sRAGE), advanced glycation endproducts-carboxymethyllysine (AGE-CML), methylglyoxal (MG), asymmetric dimethylarginine (ADMA), L-arginine (L-arg), and the ratio of both (L-arg/ADMA) in 150 patients following liver transplantation (LTPL) form deceased donors.

Timepoints		Pre	T0	T1	T3	T5	T7	Healthy controls^a
TAC	(mM)	0.062; 0.018–0.106	0.093; 0.052–0.171	0.105; 0.058–0.229	0.104; 0.050–0.189	0.087; 0.049–0.188	0.079; 0.040–0.180	0.017; 0.004–0.030
sRAGE	(pg/mL)	1447.2; 944.6–2507.7	1982.3; 1271.9–3253.4	1708.0; 1017.4–3050.1	1199.3; 686.1–2391.0	900.1; 563.8–1782.7	802.6; 436.1–1503.3	430.0; 276.6–625.8
AGE-CML	(ng/mL)	1810.3; 1144.0–3327.7	1164.9; 890.9–1558.5	1430.6; 1123.4–1963.6	1692.0; 1310.6–2362.7	1823.3; 1376.2–2470.8	1817.5; 1310.3–2650.3	1249.3; 1154.5–1385.9
MG	(nM)	373.1; 291.3–521.7	477.9; 339.3–627.3	388.9; 318.2–554.5	328.4; 271.1–390.7	289.4; 229.4–356.1	275.5; 233.1–329.2	105.8; 98.7–131.7
ADMA	(µmol/L)	0.77; 0.61–0.93	0.62; 0.51–0.77	0.76; 0.63–0.94	0.90; 0.74–1.16	0.91; 0.75–1.10	0.90; 0.76–1.13	0.43; 0.37–0.51
L-arg	(µmol/L)	138.3; 87.3–199.3	54.1; 30.7–85.2	99.1; 66.4–141.6	164.8; 123.9–202.5	143.9; 108.4–189.6	119.2; 84.1–163.6	112.6; 100.8–133.0
L-arg/ADMA	(none)	177.0; 113.2–276.5	81.5; 48.3–134.6	125.0; 82.6–183.9	163.9; 126.4–230.4	148.5; 109.2–208.4	117.8; 88.3–172.5	273.5; 218.8–329.3

Data are presented as median with quartiles (Q1–Q3).
^aAs already published throughout our workgroup, median plasma levels of ADMA, L-arg, and the ratio of both (L-arg/ADMA) in healthy volunteers are presented [36]. Plasma levels of TAC, sRAGE, AGE-CML, and MG in healthy controls are also presented (previously unpublished data of RAMMSES-Trial/German Clinical Trials Register: DRKS00000505).